Our Services
Medical Information
Helpful Resources
Published on: 9/16/2026
Heartburn is a common side effect of Wegovy (semaglutide) because the medication slows stomach emptying, but persistent or severe symptoms can occasionally point to delayed gastric emptying (gastroparesis) or a peptic ulcer, especially when paired with vomiting undigested food, early fullness, upper abdominal pain, black stools, or unintended weight loss beyond what is expected. There are several important distinctions between ordinary reflux and these more serious causes, including timing, warning signs, and when to stop the drug or seek urgent care, all of which are explained below. Most cases are mild and manageable with meal size changes, food timing, and doctor-guided acid reducers, yet the details below explain when that approach is not enough. Because symptom overlap makes self-diagnosis unreliable, a quick assessment of your specific pattern is the safest next step. Take a free, instant, online symptom check to see which causes best match your symptoms and what to discuss with your prescriber right away.
Last reviewed for medical accuracy: 09/15/2025
Wegovy heartburn after starting this medication can be concerning, especially if you’re wondering whether it signals something more serious like gastroparesis or an ulcer. Here’s what you need to know, based on credible medical sources and expert guidance.
Introduction to Wegovy and Gastrointestinal Side Effects
Wegovy (semaglutide) is a prescription medication used for long-term weight management. It mimics a hormone called GLP-1, which helps you feel full, slows gastric emptying, and regulates blood sugar. Because of its effects on the stomach, some people experience gastrointestinal side effects—most commonly nausea, vomiting, diarrhea and, yes, heartburn.
Why Heartburn Happens on Wegovy
Heartburn (acid reflux) occurs when stomach acid backs up into the esophagus, causing a burning sensation in the chest. On Wegovy, heartburn after starting treatment may happen because:
Common, Mild Causes of Heartburn on Wegovy
Many people who take Wegovy experience mild to moderate heartburn that improves over time as their bodies adjust. Typical culprits include:
In most cases, simple lifestyle tweaks and over-the-counter (OTC) remedies help:
When to Worry: Gastroparesis vs. Peptic Ulcer Disease
While mild heartburn is common, persistent or severe heartburn on Wegovy could signal an underlying issue such as gastroparesis or a peptic ulcer. Here’s how to distinguish them:
Gastroparesis (“Delayed Gastric Emptying”)
Gastroparesis means the stomach empties too slowly. Wegovy intentionally slows gastric emptying, but if symptoms go beyond typical heartburn—think nausea, early fullness, bloating and vomiting of undigested food—gastroparesis may be at play.
Key symptoms:
Peptic Ulcer Disease (Ulcer)
An ulcer is a sore in the lining of the stomach or the first part of the small intestine. Though less common on Wegovy, ulcer symptoms can overlap with heartburn.
Key symptoms:
When to Seek Medical Advice Immediately
Certain symptoms may indicate a serious complication and warrant prompt evaluation:
Evaluating Your Symptoms
If you’re experiencing ongoing discomfort, consider using a free, online symptom check, using the doctor approved Ubie Symptom Checker to get personalized guidance and help you decide whether to seek medical care right away.
Diagnostic Steps Your Doctor May Recommend
To determine whether you have gastroparesis, an ulcer or simple reflux, your healthcare provider might suggest:
Managing Gastroparesis on Wegovy
If you’re diagnosed with gastroparesis, your doctor may suggest:
Treating an Ulcer While on Wegovy
If an ulcer is discovered, treatment typically involves:
Preventing Heartburn and Related Issues on Wegovy
Even if you don’t have gastroparesis or an ulcer, you can take steps to limit heartburn and reflux:
When in Doubt, Talk to Your Doctor
If you ever experience life-threatening or serious symptoms—especially vomiting blood, passing black stools, severe pain or difficulty breathing—seek medical attention immediately. For non-urgent concerns, schedule an appointment to review your symptoms, medications and any needed diagnostic tests.
Key Takeaways
Remember, while heartburn on Wegovy is usually manageable, staying alert to warning signs can help you catch and treat any complications early. If you have concerns, speak to your healthcare provider.
(References)
* Hoofnagle JH. Weight Loss Agents. 2012. PMID: 31644235.
* Mitchell BG, Collier SA, Gupta N. Roux-en-Y Gastric Bypass. 2026 Jan. PMID: 31985950.
* Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022;13:1043789. doi: 10.3389/fendo.2022.1043789. Epub 2022 Dec 7. PMID: 36568085; PMCID: PMC9770009.
* Goldney J, Sargeant JA, Davies MJ. Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy. Diabetologia. 2023 Oct;66(10):1832-1845. doi: 10.1007/s00125-023-05988-3. Epub 2023 Aug 19. PMID: 37597048; PMCID: PMC10474214.
* Aldhaleei WA, Abegaz TM, Bhagavathula AS. Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort. Pharmaceuticals (Basel). 2024 Feb 2;17(2). doi: 10.3390/ph17020199. Epub 2024 Feb 2. PMID: 38399414; PMCID: PMC10891568.
* Santos LB, Mizubuti GB, da Silva LM, Silveira SQ, Nersessian RSF, Abib ACV, Bellicieri FN, Lima HO, Ho AM, Dos Anjos GS, de Moura DTH, de Moura EGH, Vieira JE. Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: A retrospective single center observational study. J Clin Anesth. 2024 Dec;99:111668. doi: 10.1016/j.jclinane.2024.111668. Epub 2024 Oct 30. PMID: 39476514.
* Himmerich H. [Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?]. Nervenarzt. 2025 May;96(3):247-254. doi: 10.1007/s00115-025-01813-x. Epub 2025 Mar 5. PMID: 40042613; PMCID: PMC12058874.
* Anastasiou IA, Tentolouris A, Sarantis P, Katsaouni A, Rebelos E, Mourouzis I, Pantos C, Tentolouris N. Semaglutide Enhances Cellular Regeneration in Skin and Retinal Cells In Vitro. Pharmaceutics. 2025 Aug 27;17(9). doi: 10.3390/pharmaceutics17091115. Epub 2025 Aug 27. PMID: 41012453; PMCID: PMC12473120.
* Noronha JC, Van Gaal LF, Neeland IJ, Fitch A, Pfeiffer AF, Chiavaroli L, Kendall CW, Sievenpiper JL. Optimizing GLP-1 therapies for obesity and diabetes management. Obes Pillars. 2025 Dec;16:100222. doi: 10.1016/j.obpill.2025.100222. Epub 2025 Oct 24. PMID: 41322078; PMCID: PMC12661421.
* Comisi JC. Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoring. Clin Oral Investig. 2026 Sep 14;30(10). doi: 10.1007/s00784-026-07135-9. Epub 2026 Sep 14. PMID: 42734711.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.